TRIM5α and HIV-1 CA proteins were purified, and recombinant TRIM5α/CA complexes were prepared as described (7, 8). For this study, we used TRIM5α from African green monkey because this variant is active against HIV-1 and efficiently assembles into hexagonal lattices in vitro (7). The recombinant TRIM5α protein contained an L81F mutation in the RING domain that allows in vitro coassembly with HIV-1 CA more efficiently than wild type and does not affect the ubiquitination activity of the RING domain or overall restriction activity of the protein.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.